Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance

Vanguard Growth Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Vanguard Growth Index Fund ETF — how do they compare? GSK plc trades at $50.38 (market cap $102.60B), while Vanguard Growth Index Fund ETF trades at $88.98. The key difference: GSK plc pays a 3.57% dividend while Vanguard Growth Index Fund ETF pays none, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.

GSKVUG
Market Cap
$102.60B
Sector
HealthSector/Thematic
52-Week High
$61.18$90.29
52-Week Low
$38.22$70.00
Enterprise Value
$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Vanguard Growth Index Fund ETF

Vanguard Growth ETF (VUG) trades at $89.01, down 0.19% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights strong institutional buying, with multiple firms increasing stakes by over 500% in Q2 2026 (Defense World, August 2026). The ETF focuses on large-cap growth stocks, benefiting from exposure to tech leaders like Microsoft.

The outlook remains positive given institutional accumulation and growth stock momentum, though high RSI levels suggest near-term consolidation risk. Key risks include market volatility and sector concentration, but long-term growth exposure aligns with bullish analyst sentiment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK

About Vanguard Growth Index Fund ETF

VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.

Read more on VUG